Estimating Demand for Potential Disease modifying Therapies for Alzheimer’s disease in the UK
Our aim is to estimate the scale of real-world demand in the UK for new monoclonal antibodies for Alzheimer’s given that these have recently received FDA approval and their arrival in the UK is potentially imminent.